Clinical Practice Guidelines ( 8 th Edition ) College of Chest Physicians Evidence-Based and Thrombolytic Treatment : American Hemorrhagic Complications of Anticoagulant

2008;133;257-298 Chest Sam Schulman, Rebecca J. Beyth, Clive Kearon and Mark N. Levine Clinical Practice Guidelines (8th Edition) College of Chest Physicians Evidence-Based and Thrombolytic Treatment: American Hemorrhagic Complications of Anticoagulant http://chestjournal.org/cgi/content/abstract/133/6_suppl/257S and services can be found online on the World Wide Web at: The online version of this article, along with updated information ). ISSN: 0012-3692. http://www.chestjournal.org/misc/reprints.shtml ( of the copyright holder may be reproduced or distributed without the prior written permission Northbrook IL 60062. All rights reserved. No part of this article or PDF by the American College of Chest Physicians, 3300 Dundee Road, 2007 Physicians. It has been published monthly since 1935. Copyright CHEST is the official journal of the American College of Chest

[1]  M. Prins,et al.  Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. , 2010, The Cochrane database of systematic reviews.

[2]  E. J. PubMed Citation,et al.  An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction , 2009 .

[3]  W. Frishman.  Bivalirudin for Patients with Acute Coronary Syndromes , 2007 .

[4]  H. Yonas,et al.  Reduced Pretreatment Ipsilateral Middle Cerebral Artery Cerebral Blood Flow Is Predictive of Symptomatic Hemorrhage Post–Intra-Arterial Thrombolysis in Patients With Middle Cerebral Artery Occlusion , 2006, Stroke.

[5]  P. Morange,et al.  Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. , 2006, Blood.

[6]  R. Levine,et al.  Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. , 2006, Chest.

[7]  Salim Yusuf,et al.  Comparison of fondaparinux and enoxaparin in acute coronary syndromes. , 2006, The New England journal of medicine.

[8]  S. Yusuf,et al.  Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. , 2006, JAMA.

[9]  M. Prins,et al.  Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial , 2006, BMJ : British Medical Journal.

[10]  G. Wells,et al.  A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. , 2005, Archives of internal medicine.

[11]  Palle Petersen,et al.  Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. , 2005, JAMA.

[12]  H. Büller,et al.  Fondaparinux or enoxaparin for initial treatment of symptomatic deep venous thrombosis: Randomized trial , 2004 .

[13]  A. Greinacher,et al.  Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. , 2004, Blood.

[14]  A. Salvador,et al.  Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. , 2004, Journal of the American College of Cardiology.

[15]  J. Eikelboom,et al.  Thrombolysis Compared With Heparin for the Initial Treatment of Pulmonary Embolism: A Meta-Analysis of the Randomized Controlled Trials , 2004, Circulation.

[16]  N. Kleiman,et al.  Argatroban Anticoagulation in Conjunction with Glycoprotein IIb/IIIa Inhibition in Patients Undergoing Percutaneous Coronary Intervention: An Open-Label, Nonrandomized Pilot Study , 2004, Journal of Thrombosis and Thrombolysis.

[17]  A. Woolfenden,et al.  Argatroban Anticoagulation in Patients With Acute Ischemic Stroke (ARGIS-1): A Randomized, Placebo-Controlled Safety Study , 2004, Stroke.

[18]  P. Prandoni,et al.  Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. , 2004, Archives of internal medicine.

[19]  J. Douketis,et al.  Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor , 2004, Journal of thrombosis and haemostasis : JTH.

[20]  T. Chan,et al.  Hemorrhagic complications of anticoagulant therapy in Chinese patients. , 2004, Journal of the Chinese Medical Association : JCMA.

[21]  F. Van de Werf,et al.  Argatroban and Alteplase in Patients with Acute Myocardial Infarction: The ARGAMI Study , 2000, Journal of Thrombosis and Thrombolysis.

[22]  James Douketis,et al.  Clinical Impact of Bleeding in Patients Taking Oral Anticoagulant Therapy for Venous Thromboembolism , 2003, Annals of Internal Medicine.

[23]  S. Olsson,et al.  Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial , 2003, The Lancet.

[24]  A. Iorio,et al.  Low‐molecular‐weight heparin for the long‐term treatment of symptomatic venous thromboembolism: meta‐analysis of the randomized comparisons with oral anticoagulants , 2003, Journal of thrombosis and haemostasis : JTH.

[25]  M. Prins,et al.  Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. , 2003, The New England journal of medicine.

[26]  S. Schulman,et al.  Unresolved issues in anticoagulant therapy , 2003, Journal of thrombosis and haemostasis : JTH.

[27]  W. Ageno,et al.  Extended Oral Anticoagulant Therapy after a First Episode of Pulmonary Embolism , 2003, Annals of Internal Medicine.

[28]  B. Eriksson,et al.  Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. , 2003, Archives of internal medicine.

[29]  V. Kakkar,et al.  Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis , 2003, Thrombosis and Haemostasis.

[30]  Vittorio Pengo,et al.  Prevention of thromboembolism in patients with mitral stenosis and associated atrial fibrillation: effectiveness of low intensity (INR target 2) oral anticoagulant treatment , 2003, Thrombosis and Haemostasis.

[31]  E. Topol,et al.  Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. , 2003, JAMA.

[32]  T. Clarkson,et al.  Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. , 2003 .

[33]  J. Moses,et al.  Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin‐induced thrombocytopenia , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[34]  B. Eriksson,et al.  Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. , 2002, Archives of internal medicine.

[35]  Yves Gruel,et al.  Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. , 2002, Archives of internal medicine.

[36]  E. Topol,et al.  Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). , 2002, American heart journal.

[37]  M. Prins,et al.  Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. , 2002, The Cochrane database of systematic reviews.

[38]  H. White,et al.  Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial , 2001, The Lancet.

[39]  P. Armstrong,et al.  Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. , 2001, European heart journal.

[40]  R. Higashida,et al.  Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke , 2001, Neurology.

[41]  A. Mallet,et al.  Anticoagulant (Fluindione)-Aspirin Combination in Patients with High-Risk Atrial Fibrillation , 2001, Cerebrovascular Diseases.

[42]  J. Julian,et al.  Low Molecular Weight Heparin Administered once versus twice Daily in Patients with Venous Thromboembolism , 2001, Thrombosis and Haemostasis.

[43]  W. Ageno,et al.  Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. , 2001, The New England journal of medicine.

[44]  L. Kalra,et al.  Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice? , 2001, Archives of internal medicine.

[45]  A. Greinacher,et al.  A Comparison of Danaparoid and Lepirudin in Heparin-induced Thrombocytopenia , 2001, Thrombosis and Haemostasis.

[46]  I. Durieu,et al.  Comparison of 3 and 6 Months of Oral Anticoagulant Therapy After a First Episode of Proximal Deep Vein Thrombosis or Pulmonary Embolism and Comparison of 6 and 12 Weeks of Therapy After Isolated Calf Deep Vein Thrombosis , 2001, Circulation.

[47]  V. Kakkar,et al.  Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. , 2001, The New England journal of medicine.

[48]  S. Ebrahim,et al.  Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation , 2001, BMJ : British Medical Journal.

[49]  R. Yusen,et al.  Subcutaneous Enoxaparin Once or Twice Daily Compared with Intravenous Unfractionated Heparin for Treatment of Venous Thromboembolic Disease , 2001, Annals of Internal Medicine.

[50]  L. Ming.  Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke , 2001 .

[51]  A. Martínez,et al.  Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. , 2001, Journal of vascular surgery.

[52]  J. Ribera,et al.  Low Molecular Weight Heparin (Enoxaparin) Versus Oral Anticoagulant Therapy (Acenocoumarol) in the Long-Term Treatment of Deep Venous Thrombosis in the Elderly: a Randomized Trial , 2000, Thrombosis and Haemostasis.

[53]  H. Boccalon,et al.  Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the Vascular Midi-Pyrenees study. , 2000, Archives of internal medicine.

[54]  H. Büller,et al.  Fixed-dose, Body Weight-independent Subcutaneous LMW Heparin versus Adjusted Dose Unfractionated Intravenous Heparin in the Initial Treatment of Proximal Venous Thrombosis , 2000, Thrombosis and Haemostasis.

[55]  S. Swan,et al.  The Pharmacokinetics and Pharmacodynamics of Argatroban: Effects of Age, Gender, and Hepatic or Renal Dysfunction , 2000, Pharmacotherapy.

[56]  M. Glanz,et al.  The Sharer , 2000, Annals of Internal Medicine.

[57]  W. Newton,et al.  Preventing stroke in patients with atrial fibrillation. , 2000, The Journal of family practice.

[58]  Lain,et al.  A CLINICAL TRIAL OF VENA CAVAL FILTERS IN THE PREVENTION OF PULMONARY EMBOLISM IN PATIENTS WITH PROXIMAL DEEP-VEIN THROMBOSIS , 2000 .

[59]  J. Knottnerus,et al.  Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin , 1999, BMJ.

[60]  S. Carrera,et al.  Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. , 1999, Journal of vascular surgery.

[61]  T Moulin,et al.  Hemorrhagic transformation in acute ischemic stroke. The MAST-E study. MAST-E Group. , 1999, Stroke.

[62]  R. Giugliano,et al.  A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. , 1999, Journal of the American College of Cardiology.

[63]  T. Hastie,et al.  Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis , 1999, Annals of Internal Medicine.

[64]  E. Braunwald,et al.  Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. , 1999, American heart journal.

[65]  Samuel Z Goldhaber,et al.  Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER) , 1999, The Lancet.

[66]  G. Seabrook,et al.  Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. , 1999, Radiology.

[67]  M Gent,et al.  A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. , 1999, The New England journal of medicine.

[68]  Organisation to Assess Strategies for Ischemic Syndromes Investigators.  Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial , 1999, The Lancet.

[69]  S. Lopaciuk,et al.  Low Molecular Weight Heparin versus Acenocoumarol in the Secondary Prophylaxis of Deep Vein Thrombosis , 1999, Thrombosis and Haemostasis.

[70]  R. Giugliano,et al.  TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. , 1998, Circulation.

[71]  R. Califf,et al.  Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage. , 1998, Circulation.

[72]  G. Nante,et al.  Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. , 1998, The American journal of cardiology.

[73]  G. Boysen,et al.  Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. , 1998, Archives of internal medicine.

[74]  J. Fiessinger,et al.  Comparison of a once Daily with a twice Daily Subcutaneous Low Molecular Weight Heparin Regimen in the Treatment of Deep Vein Thrombosis , 1998, Thrombosis and Haemostasis.

[75]  Epilog Investigators,et al.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. , 1997, The New England journal of medicine.

[76]  Peter Sandercock,et al.  The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997, The Lancet.

[77]  F. Fattapposta,et al.  Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. , 1997, Stroke.

[78]  V Larrue,et al.  Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. , 1997, Stroke.

[79]  O. Linder,et al.  The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. , 1997, The New England journal of medicine.

[80]  R. Collins,et al.  Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. , 1997, Circulation.

[81]  K. Lee,et al.  Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. , 1997, Circulation.

[82]  T. N. t-P. S. S. Group,et al.  Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. , 1997, Stroke.

[83]  A. Mostbeck,et al.  Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin. , 1996, Journal of vascular surgery.

[84]  E. Antman.  Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. , 1996, Circulation.

[85]  J. Fiessinger,et al.  Once-daily Subcutaneous Dalteparin, a Low Molecular Weight Heparin, for the Initial Treatment of Acute Deep Vein Thrombosis , 1996, Thrombosis and Haemostasis.

[86]  A. Laupacis,et al.  Canadian atrial fibrillation anticoagulation study: were the patients subsequently treated with warfarin? Canadian Atrial Fibrillation Anticoagulation Study Group. , 1996, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[87]  G. Raskob,et al.  Aging and heparin-related bleeding. , 1996, Archives of internal medicine.

[88]  J. Hirsh,et al.  A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. , 1996, The New England journal of medicine.

[89]  S. Shoab,et al.  Thrombolysis for acute deep vein thrombosis. , 1996, The British journal of surgery.

[90]  R. Califf,et al.  Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. , 1995, Circulation.

[91]  B. Chaitman,et al.  Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. , 1995, The New England journal of medicine.

[92]  Olle Linder,et al.  A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism , 1995 .

[93]  M. Pini,et al.  Low Molecular Weight Heparin versus Warfarin in the Prevention of Recurrences after Deep Vein Thrombosis , 1994, Thrombosis and Haemostasis.

[94]  Stroke Investigators.  Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study , 1994, The Lancet.

[95]  M. Monreal,et al.  Comparison of Subcutaneous Unfractionated Heparin with a Low Molecular Weight Heparin (Fragmin®) in Patients with Venous Thromboembolism and Contraindications to Coumarin , 1994, Thrombosis and Haemostasis.

[96]  R. Califf,et al.  Individual risk assessment for intracranial haemorrhage during thrombolytic therapy , 1993, The Lancet.

[97]  R. Diaz,et al.  After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. The Investigators of the International Tissue Plasminogen Activator/Streptoki , 1993, Circulation.

[98]  J. Durham.  Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis: Hull RD, Raskob GE, Pineo GF, et al. N Engl J Med 1992;326:975-82 , 1993 .

[99]  R. Collins,et al.  ISIS-3 and GISSI-2: no survival advantage with tissue plasminogen activator over streptokinase, but a significant excess of strokes with tissue plasminogen activator in both trials. , 1993, The American journal of cardiology.

[100]  L. Poller,et al.  Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. , 1993, The New England journal of medicine.

[101]  G. Raskob,et al.  Optimal therapeutic level of heparin therapy in patients with venous thrombosis. , 1992, Archives of internal medicine.

[102]  G. Bratt,et al.  Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg. , 1992, Thrombosis research.

[103]  ISIS-1 Collaborative Group.  ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction , 1992, The Lancet.

[104]  H. Büller,et al.  Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis , 1992, The Lancet.

[105]  J. Gore,et al.  Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial. , 1991, Circulation.

[106]  P. Prandoni,et al.  A Randomised Trial of Subcutaneous Low Molecular Weight Heparin (CY 216) Compared with lntravenous Unfractionated Heparin in the Treatment of Deep Vein Thrombosis , 1991, Thrombosis and Haemostasis.

[107]  Bernard Rosner,et al.  The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. , 1990, The New England journal of medicine.

[108]  G. Raskob,et al.  Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. , 1990, The New England journal of medicine.

[109]  GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. , 1990, Lancet.

[110]  P. Stevenson,et al.  Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. , 1990, The New England journal of medicine.

[111]  A. Siegbahn,et al.  Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo. , 1989, Thrombosis research.

[112]  Palle Petersen,et al.  PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION The Copenhagen AFASAK Study , 1989, The Lancet.

[113]  L. Bolognese,et al.  RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.

[114]  D. Doyle,et al.  Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. A randomized trial. , 1987, Annals of internal medicine.

[115]  A. Wycherley,et al.  SAFETY AND EFFICACY OF WARFARIN STARTED EARLY AFTER SUBMASSIVE VENOUS THROMBOSIS OR PULMONARY EMBOLISM , 1986, The Lancet.

[116]  G. Raskob,et al.  Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. , 1986, The New England journal of medicine.

[117]  J. Hirsh.  Heparin induced bleeding. , 1984, Nouvelle revue francaise d'hematologie.

[118]  B. Ljungberg,et al.  Subcutaneous administration of heparin. A randomised comparison with intravenous administration of heparin to patients with deep-vein thrombosis. , 1982, Thrombosis research.

[119]  J. Hirsh,et al.  Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. , 1982, The New England journal of medicine.

[120]  B. Fagher,et al.  Heparin treatment of deep vein thrombosis. Effects and complications after continuous or intermittent heparin administration. , 2009, Acta medica Scandinavica.

[121]  J. Wilson,et al.  Heparin therapy in venous thromboembolism. , 1981, The American journal of medicine.

[122]  James E. Wilson,et al.  Low-Dose Heparin Therapy in the Long-Term Management of Venous Thromboembolism , 1980 .

[123]  P. G. Bentley,et al.  An objective study of alternative methods of heparin administration. , 1980, Thrombosis Research.

[124]  M Gent,et al.  Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. , 1979, The New England journal of medicine.

[125]  J. Wilson,et al.  Heparin therapy: a randomized prospective study. , 1979, American heart journal.

[126]  M. Mant,et al.  HÆMORRHAGIC COMPLICATIONS OF HEPARIN THERAPY , 1977, The Lancet.

[127]  E. Crowell,et al.  Randomized prospective trial of continuous vs intermittent heparin therapy. , 1976, JAMA.

[128]  E W Salzman,et al.  Management of heparin therapy: Controlled prospective trial. , 1975, The New England journal of medicine.

[129]  S Shapiro,et al.  Efficacy and toxicity of heparin in relation to age and sex. , 1968, The New England journal of medicine.